 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...2627282930313233343536...208209» |
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Mesenteric Artery Dissection Aneurysm Associated with Apatinib in a Prostate Cancer Patient: A Case Report and Literature Review. (Pubmed Central) - Aug 11, 2025
As clinicians, it is imperative to remain vigilant against potential complications such as arterial dissection and aneurysm, while conducting meticulous evaluations of associated risks. Notably, this article serves solely as a reference and does not advocate for the adjustment of treatment protocols on this basis.
- | Erbitux (cetuximab) / Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed: Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients (clinicaltrials.gov) - Aug 8, 2025
P2, N=40, Active, not recruiting, Sponsor: Fudan University
Notably, this article serves solely as a reference and does not advocate for the adjustment of treatment protocols on this basis. Recruiting --> Active, not recruiting
- | SHR7280 / Jiangsu Hengrui Pharma, Haduvio (nalbuphine ER) / Trevi Therap
Journal: Relative Bioavailability of Single-Dose Oral Administration of Two SHR7280 Formulations (Dry Suspension and Tablets) in (Pubmed Central) - Aug 8, 2025
P1
The safety profile of two formulations was favorable. No serious adverse events or adverse drug reactions were reported.
- HRS-7535 / Kailera Therapeutics
Efficacy and safety of a novel oral small molecule GLP-1RA (HRS-7535) in Chinese patients with type 2 diabetes inadequately controlled by metformin and SGLT2 inhibitor (Station 23) - Aug 8, 2025 - Abstract #EASD2025EASD_2293;
P2
HRS-7535 achieved significant HbA1c reduction in Chinese pts with T2DM inadequately controlled on metformin and an SGLT2 inhibitor, and exhibited a safety profile consistent with other GLP-1RAs. These data support further clinical development of HRS-7535 for T2DM treatment.
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
Enrollment open, Trial initiation date: PISTIAS-2: PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (clinicaltrials.gov) - Aug 7, 2025
P4, N=300, Recruiting, Sponsor: Peking Union Medical College Hospital
These data support further clinical development of HRS-7535 for T2DM treatment. Not yet recruiting --> Recruiting | Initiation date: May 2025 --> Sep 2025
- || HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies (clinicaltrials.gov) - Aug 7, 2025
P3, N=0, Withdrawn, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: May 2025 --> Sep 2025 N=107 --> 0 | Trial completion date: Jun 2024 --> Jul 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2024 --> Jul 2025
- | imrecoxib (BAP 909) / Jiangsu Hengrui Pharma, Dynastat (parecoxib) / Pfizer
Journal: Parecoxib sequential with imrecoxib for occurrence and remission of severe acute pancreatitis: a multicentre, double-blind, randomised, placebo-controlled trial. (Pubmed Central) - Aug 7, 2025
N=107 --> 0 | Trial completion date: Jun 2024 --> Jul 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2024 --> Jul 2025 Parecoxib sequential with imrecoxib was effective and well tolerated in reducing the occurrence and duration of SAP and local complications through suppression of systemic inflammatory response, leading to decreased morbidity.
- | Oncorine (recombinant human adenovirus type 5) / Mergen Ltd.
Trial primary completion date: PTCA199-8: Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 7, 2025
P2, N=30, Not yet recruiting, Sponsor: Fudan University
Parecoxib sequential with imrecoxib was effective and well tolerated in reducing the occurrence and duration of SAP and local complications through suppression of systemic inflammatory response, leading to decreased morbidity. Trial primary completion date: Jan 2026 --> Jan 2028
- |||| New P2 trial: A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer (clinicaltrials.gov) - Aug 7, 2025
P2, N=200, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal: Combination of drug-eluting bead transarterial chemoembolization and PD-1 inhibitor for treatment of unresectable head and neck squamous cell carcinoma: an initial, short-term clinical experience in a single-center retrospective cohort study. (Pubmed Central) - Aug 7, 2025
One month after the first treatment, the scores of physical function, emotional function and general health status increased, and the scores of pain, insomnia and anorexia decreased, and quality of life was significantly improved. Combination of DEB-TACE with PD-1 inhibitors is safe and effective for treatment of unresectable HNSCC, significantly improves quality of life, and warrants clinical promotion and application.
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Evaluation of the Impact of Remimazolam Tosylate on Cardiac Function during Anesthesia Induction and Maintenance in Patients Undergoing Abdominal Surgery Based on Transesophageal Echocardiography (EUDRACT) - Aug 7, 2025
P=N/A, N=64, Not yet recruiting, Sponsor: Zigong Fourth People's Hospital; Zigong Fourth People's Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Camrelizumab combined with drug-loaded microsphere BACE in the treatment of locally advanced NSCLC:A prospective, single-arm clinical study (EUDRACT) - Aug 7, 2025
P=N/A, N=20, Recruiting, Sponsor: Zhoukou Central Hospital; 26
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New P4 trial: Exploratory Study of Rezvilutamide Combined with ADT as Neoadjuvant Therapy for Patients with Locally Advanced Prostate Cancer (EUDRACT) - Aug 7, 2025
P4, N=68, Not yet recruiting, Sponsor: The First Affiliated Hospital of AFMU (Xijing Hospital); The First Affiliated Hospital of AFMU (Xijing Hospital)
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Comparison of Efficacy and Safety Between Two Administration Modes of Tegileridine for Postoperative Pain Management: A Randomized Controlled Study (EUDRACT) - Aug 7, 2025
P=N/A, N=138, Not yet recruiting, Sponsor: Weifang People's Hospital; Weifang People's Hospital
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New trial, Real-world evidence: Real-World Study on the Clinical Efficacy and Safety of Vunakizumab in the Treatment of Moderate-to-Severe Plaque Psoriasis (EUDRACT) - Aug 7, 2025
P=N/A, N=50, Not yet recruiting, Sponsor: Dematology Hospital of Southern Medical University; Dematology Hospital of Southern Medical University
- | Herceptin (trastuzumab) / Roche
New trial: A multicenter, single arm clinical study on the treatment of newly diagnosed primary immune thrombocytopenia in adults with the combination of Herceptin and high-dose dexamethasone (EUDRACT) - Aug 7, 2025
P=N/A, N=89, Not yet recruiting, Sponsor: Southern Medical University Southern Hospital; Southern Medical University Southern Hospital
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P4 trial: A Prospective, Multicenter Study on the Efficacy and Safety of Ivarmacitinib in the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis(IMPROVE-RA) (EUDRACT) - Aug 7, 2025
P4, N=1000, Not yet recruiting, Sponsor: Nanjing DrumTower Hospital of Nanjing University Medical School; Nanjing DrumTower Hospital of Nanjing University Medical School
- | SHR-A2102 / Jiangsu Hengrui Pharma
New P1/2 trial: A study on the treatment of high-risk non-muscle-invasive bladder cancer with antibody-drug conjugate intravesical perfusion (EUDRACT) - Aug 7, 2025
P1/2, N=42, Not yet recruiting, Sponsor: Shanghai General Hospital; Shanghai General Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Prediction of efficacy and construction of prognostic model for conversion therapy with camrelizumab, apatinib combined with XELOX regimen in advanced gastric cancer (EUDRACT) - Aug 7, 2025
P=N/A, N=150, Not yet recruiting, Sponsor: The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: A single-arm, prospective clinical study on the consolidation therapy of adebrelimab for locally advanced non-small cell lung cancer that is not suitable for chemotherapy and unresectable (EUDRACT) - Aug 7, 2025
P4, N=32, Not yet recruiting, Sponsor: HenanCancerHospital; HenanCancerHospital
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P2 trial: Efficacy and Safety of Dalpiciclib, Exemestane, and Goserelin as Neoadjuvant Therapy in Premenopausal HR-positive, HER2-negative Breast Cancer Patients: A Phase 2 Clinical Trial (EUDRACT) - Aug 7, 2025
P2, N=86, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Observation and exploratory study on the efficacy and safety of ultrasound-guided microwave ablation combined with targeted immunotherapy for advanced liver cancer (EUDRACT) - Aug 7, 2025
P=N/A, N=70, Not yet recruiting, Sponsor: Henan Cancer Hospital; Henan Cancer Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: Neoadjuvant SBRT followed by adebrelimab and platinum-based chemotherapy for operable stage II-III non-small cell lung cancer:A single-center, single-arm, clinical study (EUDRACT) - Aug 7, 2025
P4, N=48, Not yet recruiting, Sponsor: Nanjing Drum Tower hospital; Nanjing Drum Tower hospital
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: Study on the efficacy, safety and postoperative cognitive dysfunction of continuous infusion of remimazolam toluesulfonate in PFNA surgery for elderly patients (EUDRACT) - Aug 7, 2025
P4, N=80, Recruiting, Sponsor: The Fourth People's Hospital of Zigong City; The Fourth People's Hospital of Zigong City
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P4 trial: A Study on the Efficacy and Safety of Herombopag in the Prevention of Chemotherapy-Induced Thrombocytopenia (CIT) in Patients with Gastrointestinal Tumors (EUDRACT) - Aug 7, 2025
P4, N=26, Recruiting, Sponsor: Shanghai Changhai Hospital; Shanghai Changhai Hospital
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
New P1/2 trial: Maintenance Therapy with TKIs for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase II Multicenter, Controlled Clinical Study (EUDRACT) - Aug 7, 2025
P1/2, N=330, Recruiting, Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: JAK1 inhibitor combined with Camrelizumab as first-line therapy for PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (EUDRACT) - Aug 6, 2025
P2, N=30, Not yet recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | AiTan (rivoceranib) / HLB Bio Group
New P4 trial: Clinical Study on the Efficacy of Apatinib Combined with CapeOx in the First-Line Treatment of Advanced Colorectal Cancer Based on MMR and APC Subtyping (EUDRACT) - Aug 6, 2025
P4, N=103, Not yet recruiting, Sponsor: Southern Hospital Ganzhou Hospital (Ganzhou People's Hospital); Southern Hospital Ganzhou Hospital (Ganzhou People's Hospital)
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Comparative Analysis of Serum and Urine Metabolomics: The Impact of Remimazolam Tosilate Application During General Anesthesia on Postoperative Delirium (EUDRACT) - Aug 6, 2025
P=N/A, N=160, Not yet recruiting, Sponsor: The Affiliated Hospital of Guizhou Medical University; The Affiliated Hospital of Guizhou Medical University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: A single-arm, prospective clinical study on the perioperative treatment of locally advanced squamous cell carcinoma of the head and neck with adebrelimab combined with apatinib mesylate (EUDRACT) - Aug 6, 2025
P4, N=30, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
New P1 trial: An Exploration of the Clinical Efficacy of PCSK9 Inhibitors in Combination With Neoadjuvant Chemotherapy in the Treatment of Breast Malignancies: A Prospective Multicenter Randomized Controlled Clinical Trial (EUDRACT) - Aug 6, 2025
P1, N=60, Not yet recruiting, Sponsor: The First Hospital of Lanzhou University; The First Hospital of Lanzhou University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: A single-arm, prospective clinical study of camrelizumab combined with albumin-bound paclitaxel as first-line treatment for patients with advanced non-small cell lung cancer who are not suitable for platinum-based chemotherapy (EUDRACT) - Aug 6, 2025
P=N/A, N=37, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
- | Lonsurf (trifluridine/tipiracil) / Otsuka, AiTan (rivoceranib) / HLB Bio Group
New P4 trial: A study on the efficacy and safety of combining Trifluridine and Tipiracil Hydrochloride Tablets (TAS-102) with apatinib in the treatment of advanced gastric cancer patients who have failed first-line therapy (EUDRACT) - Aug 6, 2025
P4, N=39, Not yet recruiting, Sponsor: Qinghai University Affiliated Hospital; Qinghai University Affiliated Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: effect of tegileridine fumarate injection on postoperative gastrointestinal function in elderly patients undergoing laparoscopic colorectal cancer surgery (EUDRACT) - Aug 6, 2025
P=N/A, N=114, Not yet recruiting, Sponsor: The First People
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P4 trial: Efficacy and Safety of Ivarmacitinib in Patients with Polymyalgia Rheumatica: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study (EUDRACT) - Aug 6, 2025
P4, N=80, Not yet recruiting, Sponsor: The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Evaluating the Safety and Efficacy of Tegileridine for Postoperative Analgesia After Gynecologic Laparoscopic Surgery: A Single-Center, Randomized, Double-Blind, Active-Controlled Study (EUDRACT) - Aug 6, 2025
P=N/A, N=158, Not yet recruiting, Sponsor: Ruijin hospital, Shanghai; Ruijin hospital, Shanghai
- | remifentanil / Generic mfg.
New trial: A Study Assessing Heart Rate Variability During Anesthesia Induction with Remimazolam Besylate and Remifentanil Coadministration in Elderly Patients. (EUDRACT) - Aug 6, 2025
P=N/A, N=152, Not yet recruiting, Sponsor: The Affiliated Hospital of Guizhou Medical University; The Affiliated Hospital of Guizhou Medical University
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P4 trial: A Multi-Center, Randomized, Controlled Trial of Ivarmacitinib in IgG4-Related Disease (EUDRACT) - Aug 6, 2025
P4, N=88, Not yet recruiting, Sponsor: Beijing Friendship Hospital Affiliated to Capital Medical University; Beijing Friendship Hospital Affiliated to Capital Medical University
- | AiTan (rivoceranib) / HLB Bio Group
New trial: Clinical Study on Efficacy and Safety of Aderbelimab Combined with Low-dose Apatinib in Maintenance Treatment of Extensive-stage Small Cell Lung Cancer (EUDRACT) - Aug 6, 2025
P=N/A, N=60, Not yet recruiting, Sponsor: The Second People's Hospital of Fuyang; The Second People's Hospital of Fuyang
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Study of combination of camrelizumab and apatinib for the neoadjuvant treatment of TNBC with TILs>10% (EUDRACT) - Aug 6, 2025
P2, N=58, Recruiting, Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- | SHR-1819 / Jiangsu Hengrui Pharma
New P1/2 trial: A Phase Ib/Il Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to severe Atopic Dermatitis (EUDRACT) - Aug 6, 2025
P1/2, N=50, Recruiting, Sponsor: The First Hospital of China Medical University; The First Hospital of China Medical University
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New trial: Clinical Study on Thrombocytopenia Induced by T-DM1 Adjuvant Intensification Therapy for Primary Prevention of HER2-Positive Breast Cancer with ?Herombopag Olamine Tablets? (EUDRACT) - Aug 6, 2025
P=N/A, N=56, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
- | Cosentyx (secukinumab) / Novartis
New P4 trial: The efficacy of secukinumab in treating active ankylosing spondylitis and the situation of different dosage reduction regimens after achieving treatment targets: A multicenter prospective cohort study (EUDRACT) - Aug 6, 2025
P4, N=238, Not yet recruiting, Sponsor: First Affiliated Hospital of Kunming Medical University; First Affiliated Hospital of Kunming Medical University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: TASK-05: HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) (clinicaltrials.gov) - Aug 6, 2025
P2, N=45, Not yet recruiting, Sponsor: Fudan University
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New trial: An Open-Label, Single-Center, Exploratory Phase ? Study of Fluzoparib With or Without Capecitabine as Maintenance Therapy for Recurrent or Metastatic Pancreatic Cancer (EUDRACT) - Aug 6, 2025
P=N/A, N=59, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Efficacy and Safety of Sequential Maintenance Therapy with Camrelizumab Combined with Apatinib after Radical Radiotherapy for FIGO Stage III - IVA Cervical Cancer: A Single - arm, Single - center, Exploratory Clinical Study (EUDRACT) - Aug 6, 2025
P=N/A, N=30, Recruiting, Sponsor: CAS Hefei Cancer Hospital; CAS Hefei Cancer Hospital
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New trial, Platinum sensitive: Gene Expression Profiling for Predicting the Treatment Response of Patients with BRCA(wild type) or HRD- Platinum Sensitive Ovarian Cancer to Fuzuloparib Capsules (EUDRACT) - Aug 6, 2025
P=N/A, N=30, Not yet recruiting, Sponsor: Hefei Cancer Hospital, Chinese Academy of Sciences; Hefei Cancer Hospital, Chinese Academy of Sciences
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial, Head-to-Head: Analgesic Effect, Neuroprotective Function, and Safety Evaluation of the Biased ?-Opioid Receptor Agonist Tegileridine Fumarate in Patients Undergoing Intracranial Tumor Resection: A Single-Center Randomized Controlled Non-Inferiority Trial (EUDRACT) - Aug 6, 2025
P4, N=450, Not yet recruiting, Sponsor: The Second People's Hospital of Guiyang; The Second People's Hospital of Guiyang
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1/2 trial: A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 6, 2025
P1/2, N=68, Recruiting, Sponsor: Fudan University
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P2 trial, Checkpoint inhibition: A prospective phase II clinical trial evaluating the efficacy and safety of chemotherapy combined with immune checkpoint inhibitors and ivarmacitinib in first-line treatment of extensive stage small cell lung cancer (EUDRACT) - Aug 6, 2025
P2, N=30, Not yet recruiting, Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences